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Background and the purpose of the study: A common approach in cancer chemotherapy is development of
drugs that interrupt the mitosis phase of cell division. Dimethylenastron is a known kinesin inhibitor. In this study,
six novel dimethylenastron analogues (4a-f), in which 3-hydroxyphenyl substituent has been replaced with
substituted benzylimidazolyl, were synthesized through Biginelli reaction.
Methods: Six novel Biginelli compounds (4a-f) were synthesized through one step Biginelli reaction of imidazole
aldehydes (3a-c), dimedone and urea or thioura. In vitro cytotoxicities of prepared compounds were investigated
using MTT assay. Furthermore the ELIPA kit was implemented to study inhibitory effects of synthesized compounds
on ATPase activity of kinesin by measuring of organic phosphate.
Results: Our results indicated that analogue 4c is the most toxic and analogues 4f, 4b and dimethylenasteron were
less cytotoxic in compare with other analogues. On the other hand, analogue 4a, 4b, 4c and 4e showed stronger
Kinesin inhibition as compared with analogue 4f and dimethylenasteron. None of synthesized compounds were as
potent kinesin inhibitor as Taxol. Docking analysis revealed that hydrogen bond formation and hydrophobic
interactions were the key factors affecting inhibitory effects of these compounds.
Conclusion: Newly synthesized compounds were found to have moderate to good cytotoxicity against HeLa
cancer cell. Our results may be helpful in further design of dihydropyrimidine as potential anticancer agents.
Keywords: Biginelli reaction, Dihydropyrimidine, Mitotic kinesin Eg5, DimethylenastronBackground
A common approach in cancer chemotherapy is deve-
lopment of drugs that interrupt the mitosis phase of cell
division. The mitotic spindle is an important target in
cancer chemotherapy [1]. Compounds that perturb the
spindle assembly checkpoint by interfering microtubule
polymerization or depolymerization, arrest the cell cycle
in mitosis due to prevention of the microtubule dynamics.
Nowadays, Taxol, the undisputed star, which inhibit
the depolymerisation of microtubules to disassemble the* Correspondence: hadizadehf@mums.ac.ir
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reproduction in any medium, provided the ormitotic spindle during cell division, is frequently used in
cancer chemotherapy [2].
For the first time in 1999, Mayer et al., [3] identified a
novel cell-permeable small molecule, named monastrol.
Unlike taxol, monastrol as an antimitotic agent has not
exhibited neuronal cytotoxity.
Monastrol induces a mono-astral conformation of micro-
tubules by inhibiting the mitotic kinesin Eg5 [4,5].
Exploration of monastrol, commenced a new stage in
Biginelli 3,4-dihydropyrimidine-2(1H)-one chemistry. Al-
though many researches have been devoted to reveal the
anti-mitotic mechanism of monastrol in the cell cycle [6-8],
there are few examples concerning the anticancer activity
[9-11]. Leizerman et al. [12] described the antiproliferativel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pared with taxol. Since the antimitotic activity of monastrol
is not very high, structural variants could be verified to have
better activity. Russowsky et al. [13], investigated the differ-
ential antiproliferative activity of monastrol, oxo-monastrol
and oxygenated analogs on seven human cancer cell lines.
In another study, more potent analogs of monastrol such as
dimethylenastron [14] and quinazoline-2(1H)-thione [15]
(Figure 1) were provided by skeleton modifications of mon-
astrol in the parent ring by annelation across the C-5–C-6
bond. Notable work has also been dedicated to delineate
the structure-activity relationship in the monastrol deriva-
tives [16]. In this work six novel compounds (4a-f) were
synthesized through Biginelli reaction in which hydroxy-
phenyl at C-4 position in dimethylenastron has been re-
placed with substituted benzylimidazolyl (Figure 2).
Methods
Chemistry
Melting points were determined using an Electrothermal
Capillary apparatus and are uncorrected. 1H-NMR spec-
tra were recorded using Bruker AC-80 NMR spectrom-
eter. The chemical shift values are on δ scale and the
coupling constant values (J) are in ppm relative to tetra-
methylsilane as internal standard. Errors of elemental
analyses were within ±0.4% of theoretical values.
The desired compounds were synthesized by the reac-
tions outlined in Figure 2. Imidazole aldehydes [3a-c]
was synthesized as described previously [17].
General procedure for synthesis of 4a-f
The suspension of 3a-c (2 mmoles), dimedone (2 mmoles)
and urea or thiourea (2.4 mmoles) in TMSCl (0.25 ml),
DMF (0.8 ml) and acetonitrile (1.6 ml) was stirred for 4 h.
The solid was separated by centrifugation and washed
with distilled water followed by methanol. The residue
was completely dried to give compound 4.Figure 1 Monastrol (1) and dimethylenastron (2) structures.4-[1-benzyl-2-(methylthio)-1H-imidazol-5-yl)- 3,4,7,8-
tetrahydro- 7,7 dimethyl- quinazoline-2,5-(1H,6H)-diones (4a)
This compound was obtained in 44% yield; mp 169°C;
1H-NMR (DMSO-d6): 9.5(s, 1H, NH), 8 (s, 1H, NH),
7.82–6.94 (m, 6H, arom, H-imidazole), 6.21–5.44 (3H,
CH2N, C-H quinazoline), 2.91 -2.52 (m, 7H, SCH3, 6,8,
CH2 quinazoline), 1.111-0.93 (m, 6H,CH3 quinazoline).
Anal. Calcd for C21H24N4O2S: C, 63.61; H, 6.10; N,
14.13. Found: C, 63.48; H, 6.07; N, 14.07.
4-[1-benzyl-2-(methylthio)-1H-imidazol-5-yl)-1,2,3,4,7,8-
hexahydro- 7,7 dimethyl-2-thio oxoquinazoline-5-(6H)-one (4b)
This compound was obtained in 36% yield; mp 157°C;
1H-NMR (DMSO-d6): 9.5 (s, 1H, NH), 8.00 (S, 1H, NH),
7.62 –6.95 (m, 6H, arom, H-imidazole), 5.54 (3H, CH2N,
C-H quinazoline), 2.93 - 2.54 (m, 7H, SCH3, 6,8,CH2
quinazoline) 1.11-0.83 (m, 6H, CH3 quinazoline). Anal.
Calcd for C21H24N4OS2: C, 63.13; H, 5.86; N, 13.58.
Found: C, 61.27; H, 5.88; N, 13.63.
4-[1-(2-chlorobenzyl)-2-(methylthio)-1H-imidazol-5-yl]-
3,4,7,8- tetrahydro- 7,7 dimethyl quinazoline-2,5-(1H,6H)-
diones (4c)
This compound was obtained in 61% yield; mp 149°C;
1H-NMR (DMSO-d6): 9.5(s, 1H, NH), 8.1(s, 1H, NH),
7.43-6.02 (m, 5H, arom, H-imdazole), 5.53 (3H, CH2N,
C-H quinazoline), 2.82 -2.53 (m, 7H, SCH3, 6,8- CH2
quinazoline), 1.11-0.74 (m, 6H, CH3 quinazoline). Anal.
Calcd for C21H23ClN4O2S: C, 58.53; H, 5.38; N, 13.00.
Found: C, 58.68; H, 5.40; N, 12.94.
4-[1-(2-chlorobenyl)-2-methylthio-1H-imidazol-5-yl]-
1,2,3,4,7,8- hexahydro-7,7 dimethyl-2-thio oxoquinazoline-
5-(6H)-one (4d)
This compound was obtained in 58.1% yield; mp 142°C;
1H-NMR (DMSO-d6): 9.5 (s, 1H,NH), 8.13 (s, 1H, NH)
7.63-6.41 (m, 5H, arom, H-imdazole) 5.52 (3H, CH2N,
Figure 2 Synthesis of 4-imidazolyl tetrahydroquinazolines (4a-f) under Biginelli condition.
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quinazoline), 1.23-1.02 (m, 6H, CH3 quinazoline). Anal.
Calcd for C21H23ClN4OS2: C, 56.42; H, 5.19; N, 12.53.
Found: C, 56.31; H, 5.21; N, 12.45.4-[1-(4-fluorobenzyl)-2-(methylthio)-1H-imidazol-5-yl]-3,4,7,8 –
tetrahydro-7,7 dimethyl quinazoline-2,5-(1H,6H)-diones (4e)
This compound was obtained in 68.7% yield; mp
82°C; 1H-NMR (DMSO-d6): 9.52 (s, 1H, NH), 7.91
(s, 1H, NH), 7.14- 7.11 (m, 5H, arom, H-imdazole),
5.41-5.23 (3H, CH2N, C-H quinazoline), 2.81- 2.05
(m, 7H, SCH3, 6,8- CH2 quinazoline), 1.22 -0.92
(m, 6H, CH3 quinazoline). Anal. Calcd for C21H23FN4O2S:




This compound was obtained in 58% yield; mp 149°C;
1H-NMR (DMSO-d6): 9.5 (s, 1H, NH), 8.1 (s, 1H, NH),
7.33-7.10 (m, 5H, arom, H-imdazole), 5.43 (3H, CH2N,
C-H quinazoline), 2.85- 2.12 (m, 7H, SCH3, 6,8-CH2 qui-
nazoline), 2.81 -2.43 (m, 3H, SCH3), 1.22-0.94 (m, 6H,
CH3 quinazoline). Anal. Calcd for C21H23FN4OS2: C,58.58; H, 5.38; N, 13.01. Found: C, 58.61; H, 5.39; N,
13.06.
Docking
The X-ray crystal structure of Eg5-enastron complex
(Protein Data Bank ID: 2X7C) was obtained from the
Protein Data Bank. The three-dimensional structures of
the derivatives were constructed using molecular mech-
anic force field (MM+), pre-optimization and AM1
semiemperical calculation in Hyperchem 7 software. The
final corrected PDB file of the protein and synthesized
analogs were submitted to AutoDock tools in order to
run docking process. Docking studies were performed
by AutoDock software Version 4. Searching was con-
ducted within a specified 3D docking box (40 angstrom
in all aspects) around enastron and the number of GA
runs adjusted to 20 using Lamarckian genetic algorithm
and all other parameters set as default. At the final stage
through the docked structures of all analogs, best con-
formation was selected and saved as PDB file.
PDB files of best docked analogs along with Eg5 protein
were submitted to MOE 2007.11 (License purchased from
Chemical Computing Group by Mashhad University
Medical Sciences, http://www.chemcomp.com/ for prepar-
ing figures and running protein ligand interaction finger-
print (PLIF).
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sized compounds were also determined using MOE
2007.11 software.
Cell culture
HeLa cell line was obtained from National Cell Bank of
Iran, Pasteur Institute of Iran. Cells were cultured in
DMEM medium (Gibco, USA) supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (Gibco, USA),
100 U/ml penicillin (Biosera, UK), and 100 mg/ml
streptomycin (Biosera, UK) at 37°C in a humidified
atmosphere (95%) containing 5% CO2.
Cell viability
Cytotoxic effects of synthesized compounds were deter-
mined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay [18-20]. Briefly,
5000 HeLa cells/well were seeded in a 96-well plate and
cultured overnight. Different concentrations of synthe-
sized compounds were added to each well. After incuba-
tion for 24 h, cells were treated with MTT solution (final
concentration 0.5 mg/ml; Sigma, USA) for 4 h at 37°C.
Then, the medium was removed, and the purple formazan
crystals were dissolved in 150 μl dimethylsulfoxide
(Merck, Germany). Absorbance was measured at 545 nm
(630 nm as a reference) in Synergy H4 Hybrid Multi-
Mode Microplate Reader (Biotek, Model: H4MLFPTAD).
IC50 was calculated using CalcuSyn (BioSoft).
Kinesins activity assay
Briefly MT ELIPA master mix was prepared using 2 ml
of reaction buffer containing 15 mM PIPES pH 7, 5 mM
MgCl2, 160 μl of 1 μg/μl tubuline solution in reaction
buffer, 480 μl of ELIPA reagent 1 containing 1 mM 2-
amino-6-mercapto-7-methylpurine riboside (MESG) and
24 μl of ELIPA reagent 2 containing 0.1 units/μl of pur-
ine nucleoside phosphorylase (PNP). Final reaction mix-
ture was prepared by adding 75 μl of ELIPA master mix,
1 μl of 2.5 mg/ml kinesin heavy chain Motor (Cytoskel-
eton, Cat # KR01-A) and 20 μl of different concentra-
tions of synthesized inhibitors and Taxol. Reaction was
started by adding 8 μl of 100 mM ATP stock solution
(Sigma, Cat # A3377). Absorbance of each well was re-
corded on a kinetic mode at λ360 nm wavelength using
Synergy H4 Hybrid Multi-Mode Microplate Reader (Bio-
tek, Model: H4MLFPTAD). Phosphate standard curve
was constructed by adding 0–25 μl of 0.5 mM phosphate
stock, to ELIPA master mix (Without tubulin). Activity
of kinesin was reported as nmole Pi/min/2.5 μg kinesin.
Statistical analysis
Data are expressed as mean ± SD. Statistical analyses
were performed with ANOVA followed by Tukey–
Kramer test to compare the differences between means.Differences were considered statistically significant when
P < 0.05.Results and discussion
Chemistry
In this study the new dimethylenastron derivatives (4a-f)
were produced by substitution of 3-hydroxyphenyl in
dimethylenastron with substituted benzyl imidazolyl under
Biginelli condition.
The purity of the compounds was checked by TLC
and melting points. The structure of the compounds
was confirmed on the basis of its 1H NMR spectral data
and elemental analyses. All spectral data are in accord-
ance with assigned structures. In IR spectra, N-H and
C-O stretching bands were observed at spectra expected
values. In the 1H NMR spectra, methyl protons were
seen at 0.90-1.00 ppm as separated singlets. Aromatic,
methylene, methine and NH protons were found at
expected values.Docking analysis
Accuracy of docking protocol was examined by docking
enastron in active site of Eg5 enzyme. Figure 3 shows
docked enastron and co-crystallized one in almost same
position among the receptor (RMSD = 1.24Ǻ) that con-
firmed validation of docking protocol. All dimethylenas-
tron derivatives were docked into active site of Eg5.
Table 1 shows estimated free energy of binding and
calculated ki of synthesized compounds extracted from
docking studies, these data in addition to Figure 4 which
indicates synthetic ligands were in suitable position be-
tween active site of enzyme approve suitable interaction
between ligands and protein.
According to PLIF, the most consistence interaction is
H-bound between side chain of Glu116 and nitrogen
atom on quinazoline ring. Compounds 4a, 4b, 4c and
4d have shown mentioned interaction and a backbone
H-bound donor interaction was also detected between
Glu118 and nitrogen atom in imidazolic ring of com-
pound 4a. On the other hand by calculating ligand-
protein interactions using LigX module in MOE soft-
ware, except these H-bound interactions, surface contact
interactions (arene-cation) between imidazolic ring of
ligands and Arg 221 were identified. (Figure 5) Figure 5
represents 2D graph of interactions between synthesized
compound 4b and Eg5 protein calculated by LigX
module.
Docking analysis revealed that the all compounds
interacted with Eg5 in good manner and confirms the
importance of H-bound donor group in quinazoline ring
and the role of imidazole ring as well as benzene ring in
surface contact interaction on antiproliferative effects of
synthesized compounds.
Figure 3 Docked and co-crystalized enasteron in Eg5 enzyme.
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Cytotoxicity of synthesized compounds was evaluated
using MTT assay (Table 1). HeLa cells were incubated
with different concentrations of newly synthesized com-
pounds for 24 h and cytotoxicities were evaluated using
MTT assay. Our data showed that analogue 4c (X =
2-Cl Y = O, IC50: 98 ± 19 μg/ml) was the most toxic
compound among the newly synthesized compounds.
Analogue 4f (X = 4-F Y = S, IC50: 339 ± 23 μg/ml),
4b (X = H Y = S, IC50: 301 ± 22 μg/ml) and
dimethylenasteron (IC50: 338 ± 26 μg/ml) showed less
cytotoxicities.
The significant difference between cytotoxicity of ana-
logues 4f (X = 4-F Y = S, IC50: 339 ± 23 μg/ml) and 4e
(X = 4-F Y =O, IC50: 110 ± 28 μg/ml) or analogue 4b (XTable 1 Cytotoxicity on HeLa cell line (n = 5), inhibition of Kin
analogues 4a-f




4a H O 210 ± 21
4b H S 301 ± 22
4c 2-Cl O 98 ± 19
4d 2-Cl S ND** N
4e 4-F O 110 ± 28
4f 4-F S 339 ± 23
dimethylenastrone - - 338 ± 26
Taxol - - ND**
*X and Y were represented in Figure 2.
**Not determined.
***Docking results.=H Y = S, IC50: 301 ± 22 μg/ml) and 4a (X = H Y =O,
IC50: 210 ± 21 μg/ml)demonstrated the essential role of
carbonyl group at position C2 of tetrahydro-quinazoline
on antiproliferative effect of synthesized compounds.
Meanwhile there was no big difference between cyto-
toxicity of compound 4c (X = 2-Cl Y =O, IC50: 98 ±
19 μg/ml) and 4e (X = 4-F Y =O, IC50: 110 ± 28 μg/ml);
they had so much better cytotoxic effect in comparison
with compounds 4b (X = H Y = S, IC50: 301 ± 22 μg/ml)
and 4a (X = H Y =O, IC50: 210 ± 21 μg/ml). The ob-
tained results illustrated the presence of an electron
withdrawing groups (F or Cl) on the benzylimidazolyl
substituent at position C4 of tetrahydro-quinazoline
structure could increase the cytotoxicity of prepared





Calculated*** Ki (nM) for
Kinesin inhibition
72 −8.94 281.5 nM
77 −8.67 438.63 nM
79 −9.39 130.76 nM
D** −8.83 334.27 nM
96 −8.55 536.29 nM
198 −8.52 573.33 nM
210 −8.72 409.07 nM
7 ND ND
Figure 4 Map surface of docked analogs in active site of enzyme (Green: hydrophobic; Violet: H bonding; Blue: mild polar). Crystallized
enasteron is indicated by red and stick lines.
Figure 5 2D graph of interactions between synthesized compound 4b and protein made by LigX module of MOE software. In the 2D
graphs hydrophobic/aromatic residues are colored in green, whereas polar amino acids are shown in magenta. H-bonds and all π-stacking inter-
actions are represented as green dotted lines. The active site contour is also shown.
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Kinesins operate by utilizing the energy of ATP hydrolysis,
generating Pi, to move along microtubule (MT) substrates.
To determine activity of kinesins, rate of Pi production
was measured using ELIPA (Enzyme Linked Inorganic
Phosphate Assay) Biochem kit (Cytoskeleton, cat #
BK060). The assay was based on an absorbance shift
(330–360 nm) that occurred when 2-amino-6-mercapto-
7-methylpurine ribonucleoside (MESG) was catalytically
converted to 2-amino-6-mercapto-7-methylpurine in the
presence of inorganic phosphate (Pi). The reaction was
catalyzed by purine nucleoside phosphorylase (PNP). One
molecule of Pi produces one molecule of 2-amino-6-mer-
capto-7-methylpurine in an essentially irreversible reac-
tion. Thus, the absorbance at 360 nm is directly
proportional to the amount of Pi. Our data (Table 1)
showed that analogue 4a (X =H Y =O, IC50: 72 μg/ml),
4b (X =H Y = S, IC50: 77 μg/ml), 4c (X = 2-Cl Y =O, IC50:
79 μg/ml) and 4e (X = 4-F Y =O, IC50: 96 μg/ml) were
stronger Kinesin inhibitor as compared with analogue 4f
(X = 4-F Y = S, IC50: 198 μg/ml) and dimethylenasteron
(IC50: 210 μg/ml. None of our compounds were able to
inhibit kinesin as much as Taxol (IC50: 7 μg/ml).
According to kinesin inhibitory effect of analogues 4f
and 4e, the carbonyl group at C2 position of tetrahydro-
quinozoline was crucial in kinesin inhibitory activities of
synthesized compounds. On the other hand, our results
suggested that the presence of an electron withdrawing
group in benzene ring of benzylimidazolyl at position C4
of tetrahydro-quinazoline structure had no significant
effect either positive or negative on kinesin inhibitory
activity of synthesized compounds.Conclusion
In this study a series of six novel dimethylenastron ana-
logs based on Biginelli reaction were synthesized with
IC50 in the range of 98 to 210 μg/mL against HeLa cell
line. Compared with dimethylenastron, these new series
were found to have stronger antiproliferative activity
against HeLa cell line. Structural-activity relationship
study highlighted the important role of carbonyl substi-
tution at C2 position of tetrahydro-quinazoline structure
in antiproliferative and kinesin inhibitory effect of newly
synthesized compounds. The reported results could be
helpful in developing potential formulation of new anti-
cancer drugs.
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